{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:58:12Z","timestamp":1773280692865,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digital Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The rapid growth of mobile phones, automated speech recognizing personal assistants, and internet access among the elderly provides new opportunities for incorporating such technologies into clinical research and personalized medical care. Alzheimer\u2019s disease is a good test case given the need for early detection, the high rate of clinical trial failures, the need to more efficiently recruit patients for trials, and the need for sensitive and ecologically valid trial outcomes.<\/jats:p>","DOI":"10.1038\/s41746-017-0008-y","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T17:30:50Z","timestamp":1515000650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Mobile and pervasive computing technologies and the future of Alzheimer\u2019s clinical trials"],"prefix":"10.1038","volume":"1","author":[{"given":"P. Murali","family":"Doraiswamy","sequence":"first","affiliation":[]},{"given":"Vaibhav A.","family":"Narayan","sequence":"additional","affiliation":[]},{"given":"Husseini K.","family":"Manji","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jns.2017.06.030","volume":"37","author":"I Cova","year":"2017","unstructured":"Cova, I. et al. Worldwide trends in the prevalence of dementia. J. Neurol. Sci. 37, 259\u2013260 (2017).","journal-title":"J. Neurol. Sci."},{"key":"8_CR2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.trci.2016.07.001","volume":"2","author":"JL Cummings","year":"2016","unstructured":"Cummings, J. L., & Morstorf, T. & Lee, G. Alzheimer\u2019s drug-development pipeline: 2016. Alzheimers Dement. 2, 222\u2013232 (2016).","journal-title":"Alzheimers Dement."},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S0140-6736(16)31355-1","volume":"388","author":"E Topol","year":"2016","unstructured":"Topol, E. Digital medicine: empowering both patients and clinicians.  Lancet 388, 740\u2013741 (2016).","journal-title":"Lancet"},{"key":"8_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jagp.2017.04.003","volume":"25","author":"Y Moussa","year":"2017","unstructured":"Moussa, Y. et al. Mobile health technology in late-life mental illness: a focused literature review. Am. J. Geriatr. Psychiatry 25, 865\u2013872 (2017).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jalz.2009.09.003","volume":"5","author":"MC Carrillo","year":"2009","unstructured":"Carrillo, M. C., Dishman, E. & Plowman, T. Everyday technologies for Alzheimer\u2019s disease care: research findings, directions, and challenges. Alzheimers Dement. 5, 479\u2013488 (2009).","journal-title":"Alzheimers Dement."},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrd3944","volume":"12","author":"VA Narayan","year":"2013","unstructured":"Narayan, V. A. et al. Beyond magic bullets: true innovation in health care. Nat. Rev. Drug Discov. 12, 85\u201386 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"8_CR7","first-page":"102","volume":"7","author":"BE Lyon","year":"2015","unstructured":"Lyon, B. E., Austin, D. & Seelye, A. et al. Pervasive computing technologies to continuously assess Alzheimer\u2019s disease progression and intervention efficacy. Front. Aging Neurosci. 7, 102 (2015).","journal-title":"Front. Aging Neurosci."},{"key":"8_CR8","first-page":"114","volume":"3","author":"J Cummings","year":"2016","unstructured":"Cummings, J. et al. Re-engineering Alzheimer clinical trials: Global Alzheimer\u2019s Platform Network. J. Prev. Alzheimers Dis. 3, 114\u2013120 (2016).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2014.4524","volume":"72","author":"E Ray Dorsey","year":"2015","unstructured":"Ray Dorsey, E. et al. Novel methods and technologies for 21st-century clinical trials: a review. JAMA Neurol. 72, 582\u2013588 (2015).","journal-title":"JAMA Neurol."},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2215-0366(15)00454-X","volume":"3","author":"CW Ritchie","year":"2016","unstructured":"Ritchie, C. W. et al. Development of interventions for the secondary prevention of Alzheimer\u2019s dementia: the European Prevention of Alzheimer\u2019s Dementia (EPAD) project. Lancet Psychiatry 3, 179\u2013186 (2016).","journal-title":"Lancet Psychiatry"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2016.10.006","volume":"13","author":"MW Weiner","year":"2017","unstructured":"Weiner, M. W. et al. The Alzheimer\u2019s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement. 13, 561\u2013571 (2017).","journal-title":"Alzheimers Dement."},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"e0134467","DOI":"10.1371\/journal.pone.0134467","volume":"10","author":"JL Hardy","year":"2015","unstructured":"Hardy, J. L. et al. Enhancing cognitive abilities with comprehensive training: a large, online, randomized, active-controlled trial. PLoS ONE 10, e0134467 (2015).","journal-title":"PLoS ONE"},{"key":"8_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.11","volume":"3","author":"BM Bot","year":"2016","unstructured":"Bot, B. M. et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Sci. Data 3, 160011 (2016).","journal-title":"Sci. Data"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961\u2013970 (2014).","journal-title":"JAMA Neurol."},{"key":"8_CR15","first-page":"8","volume":"3","author":"DM Rentz","year":"2016","unstructured":"Rentz, D. M. et al. The feasibility of at-home iPad cognitive testing for use in clinical trials. J. Prev. Alzheimers Dis. 3, 8\u201312 (2016).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.artmed.2007.11.002","volume":"42","author":"A Almudevar","year":"2008","unstructured":"Almudevar, A., Leibovici, A. & Tentler, A. Home monitoring using wearable radio frequency transmitters. Artif. Intell. Med. 42, 109\u2013120 (2008).","journal-title":"Artif. Intell. Med."},{"key":"8_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3233\/JAD-161283","volume":"57","author":"M El Haj","year":"2017","unstructured":"El Haj, M., Gallouj, K. & Antoine, P. Google Calendar enhances prospective memory in Alzheimer\u2019s disease: a case report. J. Alzheimers Dis. 57, 285\u2013291 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fphys.2017.00361","volume":"8","author":"M El Haj","year":"2017","unstructured":"El Haj, M. Google Calendar to alleviate prospective memory compromise in a patient with very mild Alzheimer\u2019s disease. Front. Psychol. 8, 361 (2017).","journal-title":"Front. Psychol."},{"key":"8_CR19","first-page":"1","volume":"28","author":"H Imbeault","year":"2016","unstructured":"Imbeault, H. et al. Impact of AP@ LZ in the daily life of three persons with Alzheimer\u2019s disease: long-term use and further exploration of its effectiveness. Neuropsychol. Rehabil. 28, 1\u201324 (2016).","journal-title":"Neuropsychol. Rehabil."},{"key":"8_CR20","first-page":"1","volume":"12","author":"H Imbeault","year":"2016","unstructured":"Imbeault, H. et al. Can people with Alzheimer\u2019s disease improve their day-to-day functioning with a tablet computer? Neuropsychol. Rehabil. 12, 1\u201318 (2016).","journal-title":"Neuropsychol. Rehabil."},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3390\/s16121989","volume":"16","author":"B Kikhia","year":"2016","unstructured":"Kikhia, B. et al. Utilizing a wristband sensor to measure stress level for people with dementia. Sensors 16, 1989 (2016).","journal-title":"Sensors"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1017\/S104161021600243X","volume":"29","author":"AR Silva","year":"2017","unstructured":"Silva, A. R. et al. It is not only memory: effects of sensecam on improving well-being in patients with mild Alzheimer disease. Int. Psychogeriatr. 29, 741\u2013754 (2017).","journal-title":"Int. Psychogeriatr."},{"key":"8_CR23","first-page":"80","volume":"7","author":"RI Garc\u00eda-Betances","year":"2015","unstructured":"Garc\u00eda-Betances, R. I. et al. A succinct overview of virtual reality technology use in Alzheimer\u2019s disease. Front. Aging Neurosci. 7, 80 (2015).","journal-title":"Front. Aging Neurosci."},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1017\/S1355617714000344","volume":"20","author":"P Allain","year":"2014","unstructured":"Allain, P. et al. Detecting everyday action deficits in Alzheimer\u2019s disease using a nonimmersive virtual reality kitchen. J. Int. Neuropsychol. Soc. 20, 468\u2013477 (2014).","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cct.2017.08.001","volume":"62","author":"LN Gitlin","year":"2017","unstructured":"Gitlin, L. N. et al. A randomized trial of a web-based platform to help families manage dementia-related behavioral symptoms: the WeCareAdvisor\u2122. Contemp. Clin. Trials 62, 27\u201336 (2017).","journal-title":"Contemp. Clin. Trials"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-017-0008-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-017-0008-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-017-0008-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T12:33:57Z","timestamp":1671626037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-017-0008-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1038\/s41746-017-0008-y","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]},"assertion":[{"value":"31 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The technologies described in this article were selected to be illustrative of the advances being made. P.M.D. is a minor shareholder and advisor to Anthrotronix and a former advisor and grant recipient from Neuronetrix. He has also received a speaking fee from CEOs Against Alzheimer\u2019s (but has no involvement with their trial platform). He has also received research grants and\/or advisory\/speaking fees from several pharmaceutical, CRO, and technology companies for other projects, and he owns shares in Maxwell Health, Evidation, Muses Labs, Turtle Shell, and Adverse Events Inc. whose products are not discussed here. He has served as an advisor and received grants from Johnson and Johnson in the past for other projects but not in the past 3 years. V.A.N. and H.K.M. are employees and shareholders of Janssen (Johnson & Johnson) and have no direct financial conflicts of interest to declare as individuals in the technologies or registries mentioned. Janssen as a company is active in the area of Alzheimer\u2019s research and drug development. It has financially supported mobile technologies and tools being developed (mostly by other academics or entities) for Alzheimer\u2019s diagnosis, monitoring, and care-giver support as well as patient registries and platforms, such as BHR and GAP. ReVeRe is being developed by Janssen. Outside of Alzheimer\u2019s, JNJ also supports a range of mobile technologies for other therapeutic areas.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}